DELCATH SYSTEMS, INC.
DCTHNasdaqHealthcare · Surgical & Medical Instruments & Apparatus · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | $85.2M | $37.2M | $2.1M | $2.7M | $3.6M | — |
| Operating income | $660,000 | −$12.4M | −$38.2M | −$33.9M | −$24.5M | −$21.3M |
| Net income | $2.7M | −$26.4M | −$47.7M | −$36.5M | −$25.6M | −$24.2M |
| Total assets | $123.6M | $76.6M | $38.6M | $17.9M | $33.1M | $34.6M |
| Total liabilities | $12.4M | $7.8M | $22.8M | $23.7M | $21.2M | $12.6M |
| Equity | $111.2M | $68.7M | $15.8M | −$5.9M | $12.0M | $22.1M |
| EPS (diluted) | $0.07 | $-0.93 | $-2.94 | $-4.12 | $-3.59 | $-8.35 |
| Shares out. | 33.4M | 24.6M | 10.1M | 7.9M | 6.3M | 72,773 |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- 0.8%
- Net margin
- 3.2%
- Return on equity
- 2.4%
- Return on assets
- 2.2%
- Return on capital (ROCE)
- 0.6%
- Liabilities / assets
- 10.0%
- Debt / equity
- 0.11×
- Book value / share
- $3.33
- Revenue growth (YoY)
- 129.1%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- 1.26grey zone
- Accruals / assets
- −16.0%clean
- Beneish M-Score
- -2.69normal
- Piotroski F-Score
- 7/9strong
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →
Signs
● 1 severe● 1 warning● 5 good- Filed a late-filing notice (Form NT) — missed an SEC deadline
- Altman Z″ in the grey zone
- Operating margin is positive
- Revenue is growing year-over-year
- Conservative leverage (liabilities < 50% of assets)
- Positive operating cash flow
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Risk flags
late SEC filings- NT 10-Qmissed a reporting deadline ↗May 12, 2023
- NT 10-Qmissed a reporting deadline ↗Nov 9, 2018
- NT 10-Qmissed a reporting deadline ↗Aug 9, 2018
A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.
Clinical trials
ClinicalTrials.gov · ongoing · next readout first- Phase 3Active Not Recruitingreadout ~2024-03-01An Open-Label Expanded Access Study of the Melphalan/Hepatic Delivery System (HDS) in Patients With Hepatic Dominant Ocular Melanoma
- Phase 2Recruitingreadout ~2026-12Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Colorectal Cancer w/Liver Dominant Disease
- Phase 2Recruitingreadout ~2029-05Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Breast Cancer w/Liver Dominant Disease
Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Blackrock, Inc.Passive (13G)Apr 27, 2026
- Kaufman Daniel LouisPassive (13G)Mar 20, 2026
- Rosalind Advisors, Inc.Activist (13D)Feb 10, 2026
- Vivo Opportunity Fund Holdings, L.P.Passive (13G)May 15, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Pennell SandraOfficer — Chief Financial Officer | Mar 6, 2026 | Buy | 5,533 | $9.04 |
| Michel Gerard JOfficer — CHIEF EXECUTIVE OFFICER | Mar 2, 2026 | Buy | 11,200 | $8.96 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 3.4M | 6.3 | -3.3% |
| Apr 30, 2026 | 3.5M | 13.0 | -8.1% |
| Apr 15, 2026 | 3.9M | 13.8 | -2.6% |
| Mar 31, 2026 | 4.0M | 12.6 | -3.5% |
| Mar 13, 2026 | 4.1M | 8.8 | +2.9% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Director / officer change · Shareholder voteMay 14, 2026
- Results of operationsMay 7, 2026
- Other material eventMar 3, 2026
- Results of operationsFeb 26, 2026
- Results of operations · Regulation FD disclosure · Other material eventJan 12, 2026
- Other material eventNov 20, 2025
- Results of operationsNov 4, 2025
- Results of operations · Regulation FD disclosure · Other material eventOct 20, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.